Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $364.77 million. The enterprise value is $295.54 million.
Important Dates
The next confirmed earnings date is Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 73.25 million shares outstanding. The number of shares has increased by 67.19% in one year.
| Current Share Class | 73.25M |
| Shares Outstanding | 73.25M |
| Shares Change (YoY) | +67.19% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 7.98% |
| Owned by Institutions (%) | 34.68% |
| Float | 63.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.39 |
| P/TBV Ratio | 7.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.49, with a Debt / Equity ratio of 0.94.
| Current Ratio | 13.49 |
| Quick Ratio | 13.31 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.78 |
Financial Efficiency
Return on equity (ROE) is -64.58% and return on invested capital (ROIC) is -33.38%.
| Return on Equity (ROE) | -64.58% |
| Return on Assets (ROA) | -26.00% |
| Return on Invested Capital (ROIC) | -33.38% |
| Return on Capital Employed (ROCE) | -41.54% |
| Weighted Average Cost of Capital (WACC) | -0.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.00M |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.45% in the last 52 weeks. The beta is -0.90, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.90 |
| 52-Week Price Change | -37.45% |
| 50-Day Moving Average | 5.60 |
| 200-Day Moving Average | 5.55 |
| Relative Strength Index (RSI) | 42.08 |
| Average Volume (20 Days) | 1,576,596 |
Short Selling Information
The latest short interest is 12.99 million, so 17.73% of the outstanding shares have been sold short.
| Short Interest | 12.99M |
| Short Previous Month | 9.30M |
| Short % of Shares Out | 17.73% |
| Short % of Float | 20.51% |
| Short Ratio (days to cover) | 10.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.27M |
| Pretax Income | -38.18M |
| Net Income | -38.18M |
| EBITDA | -47.42M |
| EBIT | -48.27M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income Statement Balance Sheet
The company has $119.73 million in cash and $49.03 million in debt, with a net cash position of $70.70 million or $0.97 per share.
| Cash & Cash Equivalents | 119.73M |
| Total Debt | 49.03M |
| Net Cash | 70.70M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 51.92M |
| Book Value Per Share | 0.95 |
| Working Capital | 112.39M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$38.31 million and capital expenditures -$587,000, giving a free cash flow of -$38.90 million.
| Operating Cash Flow | -38.31M |
| Capital Expenditures | -587,000 |
| Free Cash Flow | -38.90M |
| FCF Per Share | -$0.53 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -67.19% |
| Shareholder Yield | -67.19% |
| Earnings Yield | -10.43% |
| FCF Yield | -10.62% |
Analyst Forecast
The average price target for CADL is $18.50, which is 271.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18.50 |
| Price Target Difference | 271.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |